Puma Biotechnology, Inc. (PBYI) Stock
Key stats
- Market cap
- $417.72M
- Price / Earnings ratio
- 17.7x
- EPS (TTM)
- $0.48
- Volume
- Loading
- 52-week high
- $11.50
- 52-week low
- $4.58
Source: third-party data provider, as of November 13, 2026
Compare with PBYI
Recent news

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
PBYI

Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
PBYI

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
PBYI

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
PBYI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 30.31
- MACD 12/26/9
- -0.40
- EMA 9 of MACD
- -0.06
- MACD histogram
- -0.34
- SMA 50
- $9.82
- Price below SMA 50
- EMA 50
- $9.65
- Price below EMA 50
- SMA 200
- $8.02
- Price above SMA 200
- EMA 200
- $8.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.10 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
PBYI

Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
PBYI

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
PBYI

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
PBYI

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
PBYI

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
PBYI

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
PBYI

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
PBYI
News tone: automated (AI) classification of the article's content, not a price prediction.
About Puma Biotechnology, Inc.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Alan H. Auerbach | Founder, Chairman, President, CEO & Secretary | 1970 |
| Mr. Maximo F. Nougues | CFO & Principal Accounting Officer | 1969 |
| Mr. Douglas Hunt B.Sc., FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer | 1965 |
| Mr. Gordon G. Esplin | Chief Accounting Officer | 1968 |
| Mr. Mariann Ohanesian | Senior Director of Investor Relations | — |
| Ms. Heather Blaber | Senior Vice President of Marketing | — |
| Mr. Roger L. Storms | Senior Vice President of Sales | — |
| Ms. Pamela Wilson BA | Senior Vice President of Clinical Operations | — |
| Dr. Petra Rietschel | Senior Vice President of Clinical Development | — |
| Mr. Kenneth Wiehe | Senior Vice President of Supply Chain & Manufacturing | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 30.31
- MACD 12/26/9
- -0.40
- EMA 9 of MACD
- -0.06
- MACD histogram
- -0.34
- SMA 50
- $9.82
- Price below SMA 50
- EMA 50
- $9.65
- Price below EMA 50
- SMA 200
- $8.02
- Price above SMA 200
- EMA 200
- $8.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.8 | +1.3 | ||||||||||
| 2022 | -22.9 | -11.9 | +22.6 | -20.8 | -16.0 | +52.4 | +5.4 | -7.9 | -9.5 | -8.8 | +100.9 | -7.2 |
| 2023 | +4.1 | -11.3 | -23.1 | -11.6 | +26.9 | +2.6 | +10.7 | +2.3 | -28.9 | -3.9 | +47.2 | +15.5 |
| 2024 | +3.8 | +27.2 | -10.0 | -4.0 | -22.2 | -14.0 | +9.5 | |||||
| 2025 | +6.4 | |||||||||||
| 2026 | -25.8 | -0.5 | +11.1 | -4.3 | +13.9 | -0.8 | +18.5 | +6.2 | +6.1 | -20.6 |




